Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
mezagitamab (TAK-079) / Takeda
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia	Active, not recruiting	2	41	Europe, Japan, US, RoW	Placebo, TAK-079	Takeda	Primary Immune Thrombocytopenia	08/24	08/24
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)	Terminated	1/2	27	Canada, US	TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj	Takeda	Relapsed and/or Refractory Multiple Myeloma (RRMM)	08/23	11/23
NCT03984097: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)	Active, not recruiting	1	50	US	TAK-079, Mezagitamab, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide	Takeda	Multiple Myeloma	02/25	02/25
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Active, not recruiting	1	16	Europe, Japan, US, RoW	Mezagitamab, TAK-079	Takeda	Kidney Disease, Glomerulonephritis	03/26	03/26